The "cavitary" type of angiogenesis by gastric cancer. Morphological characteristics and prognostic value

Journal of Cancer

Volumn 5, Issue 5, 2014, Pages 311-319

  Senchukova, Marina ^a   Kiselevsky, Mikhail V ^b  

^a ORENBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^b N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

Author keywords

Angiogenesis; Antibacterial therapy; Clinical significance; Gastric cancer; Vessels morphology

Indexed keywords

CD34 ANTIBODY; EOSIN; HEMATOXYLIN;

ADULT; AGED; ANGIOGENESIS; ANTIMICROBIAL THERAPY; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DESQUAMATION; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LAMINA PROPRIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORPHOLOGICAL TRAIT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROSPECTIVE STUDY; RADICAL RESECTION; RECURRENCE FREE SURVIVAL; STOMACH CANCER; STOMACH DISTENSION; STOMACH GLAND; STOMACH MUCOSA; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

EID: 84896989902     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.8716     Document Type: Article

References (32)

1. Folkman J. Is tissue mass regulated by vascular endothelial cells? Prostate as the first evidence. Endocrinology 1998; 139(2): 441-442. doi: 10.1210/en.139.2.441.
2. Atkin GK, Chopada A. Tumour angiogenesis: the relevance to surgeons. Ann R Coll Surg Engl. 2006; 88: 525-529. doi: 10.1308/003588406X117106.
3. Sussman LK, Upalakalin JN, Roberts MJ, et al. Blood markers for vasculogenesis increase with tumor progression in patients with breast carcinoma. Cancer Biology Therapy 2003; 2: 255-256.
4. Baluk P, Morikawa S, Haskell A, et al. Abnormalities of Basement Membrane on Blood Vessels and Endothelial Sprouts in Tumors. American Journal of Pathology 2003; 163 (5): 1801 -1815.
5. Morikawa S, Baluk P, Kaidoh T, et al. Abnormalities in Pericytes on Blood Vessels and Endothelial Sprouts in Tumors. American Journal of Pathology 2002; 160(3): 985 -1000.
6. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 5422: 1994-1998. DOI:10.1126/science.284.5422.1994.
7. Chang YS, di Tomaso E, McDonald DM, et al. Mosaic blood vessels in tumors: Frequency of cancer cells in contact with flowing blood. PNAS 2000; 97(26): 14608-14613.
8. Wang W, Lin P, Han C, et al. Vasculogenic mimicry contributes to lymph node metastasis of laryngeal squamous cell carcinoma. J Exp Clin Cancer Res. 2010; 29: 60. doi: 10.1186/1756-9966-29-60.
9. Burri PH, Hlushchuk R, Djonov V. Intussusceptive Angiogenesis: Its Emergence, Its Characteristics, and Its Significance. Developmental Dinamics 2004; 231: 474 -478. DOI: 10.1002/dvdy.20184.
10. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial cell progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 1999; 85:221-228. doi: 10.1161/ 01.RES.85.3.221.
11. Sun B, Zhang S, Ni C, et al. Correlation between melanoma angiogenesis and the mesenchymal stem cells and endothelial progenitor cells derived from bone marrow. Stem Cells Dev. 2005; 14(3):292-8.
12. [No authors listed]. TNM Classification of Malignant Tumours -7 edition. http://www.UICC.org
13. Eiro N, Vizoso FJ. Inflammation and cancer. World J Gastrointest Surg. 2012; 4(3):62-72. doi: 10.4240/wjgs.v4.i3.62.
14. Wu Y, Zhou BP. Inflammation: a driving force speeds cancer metastasis. Cell Cycle 2009; 8(20): 3267-3273.
15. De Narddo DG, Johansson M, Coussens LM. Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev. 2008; 27:11-18. DOI: 10.1007/s10555-007-9100-0.
16. Pollard JW. Trophic macrophages in development and disease. Nat Rev Immunol. 2009; 9(4):259-70. doi: 10.1038/nri2528.
17. Mantur M, Wojszel J. Cell adhesion molecules and their participation in the process of inflammation and cancerogenesis. Pol Merkur Lekarski 2008; 24(140):177-80.
18. Reiss K, Ludwig A, Saftig P. Breaking up the tie: disintegrin-like metalloproteinases as regulators of cell migration in inflammation and invasion. Pharmacol Ther. 2006; 111(3):985-1006.
19. Man Y.G. Aberrant leukocyte infiltration: a direct trigger for breast tumor invasion and metastasis. Int J Biol Sci. 2010; 6(2):129-32.
20. Man YG, Stojadinovic A, Mason J, et al. Tumor-Infiltrating Immune Cells Promoting Tumor Invasion and Metastasis: Existing Theories. J. Cancer 2013; 4(1):84-95. doi:10.7150/jca.5482.
21. Man YG, Harley R, Mason J, Gardner WA. Contributions of leukocytes to tumor invasion and metastasis: the "piggy-back" hypothesis. Cancer Epidem. 2010; 34:3-6.
22. Pawelek JM, Chakraborty AK. The cancer cell--leukocyte fusion theory of metastasis. Adv Cancer Res. 2008; 101:397-444.
23. Acs G, Dumoff KL, Solin LJ, et al. Extensive Retraction Artifact Correlates With Lymphatic Invasion and Nodal Metastasis and Predicts Poor Outcome in Early Stage Breast Carcinoma. Am J Surg Pathol. 2007; 31:129-140.
24. Acs G, Paragh G, Rakosy Z, et al. The extent of retraction clefts correlates with lymphatic vessel density and VEGF-C expression and predicts nodal metastasis and poor prognosis in early-stage breast carcinoma. Mod Pathol. 2012; 25(2):163-177. doi: 10.1038/modpathol.2011.138.
25. Zaorsky NG, Patil N, Freedman GM, Tuluc M. Differentiating lymphovascular invasion from retraction artifact on histological specimen of breast carcinoma and their implications on prognosis. J Breast Cancer 2012; 15(4):478-80.
26. Man YG. Tumor cell budding from focally disrupted tumor capsules: a common pathway for all breast cancer subtype derived invasion?. J Cancer 2010; 1:32-37. doi:10.7150/jca.1.32.
27. Man YG. A seemingly most effective target for early detection and intervention of prostate tumor invasion. J Cancer 2010; 1:63-69. doi:10.7150/jca.1.63.
28. Nagy JA, Dvorak AM, Dvorak HF. Vascular hyperpermeability, angiogenesis, and stroma generation. Cold Spring Harb Perspect Med. 2012; 2(2):a006544. doi: 10.1101/cshperspect.a006544.
29. van der Bilt JD, Borel Rinkes IH. Surgery and angiogenesis. Biochim Biophys Acta 2010; 1654:95-104. doi: 10.1016/j.bbcan.2004.01.003.
30. Mikasa K, Sawaki M, Kita E, et al. Significant survival benefit to patients with advanced non-small-cell lung cancer from treatment with clarithromycin. Chemotherapy 1997; 43(4):288-296.
31. Morris TC, Kettle PJ, Drake M, et al. Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma. Br J Haematol. 2008; 143(3):349-54. DOI: 10.1111/j.1365-2141.2008.07360.x.
32. Sauter C, Blum S. Regression of lung lesions in Hodgkin's disease by antibiotics: case report and hypothesis on the etiology of Hodgkin's disease. Am J Clin Oncol. 2003; 26(1):92-4.